| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/22/2002 | WO2002042280A3 Pyrimidine derivatives |
| 08/22/2002 | WO2002036587A3 Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| 08/22/2002 | WO2002033050A3 Methods and compositions for promoting the maturation of monocytes |
| 08/22/2002 | WO2002032869A3 Substituted heterocyclic compounds for treating multidrug resistance |
| 08/22/2002 | WO2002032404A3 Nanoparticles |
| 08/22/2002 | WO2002032377A3 Estrogen receptor modulators |
| 08/22/2002 | WO2002030932A3 N8,n13-disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents |
| 08/22/2002 | WO2002024221A3 Notch receptor agonists and uses |
| 08/22/2002 | WO2002024210A3 Halogen compounds for use in medicine |
| 08/22/2002 | WO2002008250A3 Ghrelin antagonists |
| 08/22/2002 | WO2002004412A3 Tyrosine derivatives as phosphatase inhibitors |
| 08/22/2002 | WO2002002755A3 Regulation of human thimet oligopeptidase-like enzyme |
| 08/22/2002 | WO2002000233A3 Purging of cells using viruses |
| 08/22/2002 | WO2002000001A3 HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR20, AND USES THEREOF |
| 08/22/2002 | WO2001091794A3 Vitamin d3 analogs as radiosensitizers for the treatment of cancer |
| 08/22/2002 | WO2001087328A3 Interleukin-1 inhibitors in the treatment of diseases |
| 08/22/2002 | WO2001085204A3 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 08/22/2002 | WO2001085203A3 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells |
| 08/22/2002 | WO2001080842A3 Compositions comprising a methylnogarol in combination with an antiproliferative agent |
| 08/22/2002 | WO2001074903A3 Cd20/ige-receptor like molecules and uses thereof |
| 08/22/2002 | WO2001072775A3 Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer |
| 08/22/2002 | WO2001072295A3 Compositions and methods for the therapy and diagnosis of lung cancer |
| 08/22/2002 | WO2001070982A3 Brca-1 regulators and methods of use |
| 08/22/2002 | WO2000038706A9 Methods for treating cancer and for mediating chemotaxis of dendritic cells |
| 08/22/2002 | WO2000026247A9 Ikaros isoforms and mutants |
| 08/22/2002 | WO2000023092A9 Contulakin-g, analogs thereof and uses therefor |
| 08/22/2002 | WO2000011195A9 C-myc is activated by beta-catenin and tcf-4 |
| 08/22/2002 | WO1999058143A9 Utilization of interferon alpha 5 in the treatment of viral hepatopathies |
| 08/22/2002 | US20020115858 Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
| 08/22/2002 | US20020115856 Selective cyclooxygenase-2 (COX-2) inhibitors; for example, 1-(5-Methanesulfonyl-pyridin-2-yl)-7-methoxy-3-trifluoromethyl-4,5-dihydro -1H-benzo(g)indazole |
| 08/22/2002 | US20020115853 6-(3-nitrophenyl)-3H-benzooxazol-2-one for example; contraceptives, treating hormone dependent tumors, endometriosis; progesterone receptor agonists and antagonists |
| 08/22/2002 | US20020115843 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 08/22/2002 | US20020115833 Glycoprotein for use in the treatment of kidney and blood disorders |
| 08/22/2002 | US20020115826 Enzyme inhibitor for use for use in the treatment of cell proliferative defects |
| 08/22/2002 | US20020115825 Peptide for use in the treatment of gastrointestinal inflammation and defects of the blood brain barrier |
| 08/22/2002 | US20020115716 Oral low dose butyrate compositions |
| 08/22/2002 | US20020115708 Antiestrogenic and antitumorigenic activities |
| 08/22/2002 | US20020115690 Free of alcohol and propylene glycol; surfactant; polyethylene glycol solvent having a mean molecular weight of greater than 300 but lower than 600 |
| 08/22/2002 | US20020115679 N-acyl- or N-sulfonylpiperidine substituted tricyclic benzocycloheptenepyridine derivatives |
| 08/22/2002 | US20020115677 Such as a combretastatin |
| 08/22/2002 | US20020115675 Treating particularly tumoral diseases, diseases of the lungs and respiratory tract. |
| 08/22/2002 | US20020115643 Such as enantiomorphs of 4-fluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone; antiproliferative/anticancer agents |
| 08/22/2002 | US20020115627 Phosphatonin-related gene and methods of use thereof |
| 08/22/2002 | US20020115615 A peptide compound, where a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH is replaced; anticarcinogenic and -tumor agents; hormone inhibitors; urogenital disorders |
| 08/22/2002 | US20020115613 Treatment of prostate cancer |
| 08/22/2002 | US20020115610 Isolated polypeptides that stimulate gastrointestinal smooth muscle contraction, including human; ionotropic agents; enhanced gastrointestinal motility; identifying a prokineticin receptor ligand; calcium mobilization |
| 08/22/2002 | US20020115595 Bioactive agent is covalently conjugated to an organocobalt complex's cobalt atom through a non-reactive atom in the bioactive agent molecule such as peptide, protein, nucleic acid and analogues |
| 08/22/2002 | US20020115205 Receptor protein for use in the treatment of cancer, infections, psoraisis, asthma, allergies, viral diseases, arteriosclerosis, gland, eye, autoimmune, nervous system and psychological disorders |
| 08/22/2002 | US20020115203 Proteins for use in the treatment infectious, cancers and autoimmune disease |
| 08/22/2002 | US20020115186 Peptide for use in the diagnosis, prevention, and treatment of inflammation, cancer, arteriosclerosis and degenerative defects |
| 08/22/2002 | US20020115183 Enzymatic protien for us ein prevention of tumor metastasis |
| 08/22/2002 | US20020115177 Regulation of human histone deacetylase |
| 08/22/2002 | US20020115167 Isolation of drosophila and human polynucleotides encoding PAR-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 08/22/2002 | US20020115166 Peptide for use in the treatment of pancreatic defects |
| 08/22/2002 | US20020115151 Human defensin polypeptide Def-X, genomic DNA and cDNA, composition containing them and applications to diagnosis and to therapeutic treatment |
| 08/22/2002 | US20020115138 Nucleotide sequences coding transport protein for use in treat ment of tumors |
| 08/22/2002 | US20020115120 Controlling polypetide activity in cell; obtain cell, incubate with modulator, monitor gene expression and protein activity |
| 08/22/2002 | US20020115109 Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions |
| 08/22/2002 | US20020115102 Novel protein |
| 08/22/2002 | US20020115090 Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 08/22/2002 | US20020114852 Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof |
| 08/22/2002 | US20020114848 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues |
| 08/22/2002 | US20020114816 Autoreactive peptides from human glutamic acid-decarboxylase (gad) |
| 08/22/2002 | US20020114812 Preparing cells as cancer therapy for administration to a subject with cancer comprising culturing cells in the presence of an macrophage migration inhibitory factor antagonist |
| 08/22/2002 | US20020114811 Contacting body fluid from mammal with antibody which binds to human aspartyl (asparaginyl) beta-hydroxylase (HAAH) polypeptide under conditions sufficient to form antigen-antibody complex and detecting complex |
| 08/22/2002 | US20020114810 Diagnosis and treatment of malignant neoplasms statement as to federally sponsored research |
| 08/22/2002 | US20020114809 Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 08/22/2002 | US20020114807 Administering drug comprising a substance that specifically recognizes extracellular domain of signal regulatory proteins and that inhibits functioning of pathologic myeloid cells |
| 08/22/2002 | US20020114801 Heparanase specific molecular probes and their use in research and medical applications |
| 08/22/2002 | US20020114793 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
| 08/22/2002 | US20020114781 Interleukin antagonists for suppressing autoimmune respone via reducing number of antigen-reactive lymphocytes; treatment of rheumatic diseases |
| 08/22/2002 | US20020114763 Inorganic materials for radioactive drug delivery |
| 08/22/2002 | DE10108215A1 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym A pharmaceutical combination of antagonists of angiotensin II inhibitors and angiotensin II converting enzyme |
| 08/22/2002 | DE10106647A1 Ratjadon-Derivate zum Hemmen des Zellwachstums Ratjadone derivatives for inhibiting cell growth |
| 08/22/2002 | DE10100238A1 Verfahren zur Vorhersage des Gefährdungspotentials für Karzinomerkrankungen und entzündliche Darmerkrankungen und zugehörige Tests A method for predicting the risk potential for cancer diseases and inflammatory bowel disease and related tests |
| 08/22/2002 | CA2438712A1 Method of treating of demyelinating diseases or conditions |
| 08/22/2002 | CA2438501A1 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 08/22/2002 | CA2438219A1 Sequences involved in phenomena of tumour suppression, tumour reversion apoptosis and/or virus resistance and their use as medicines |
| 08/22/2002 | CA2438215A1 Putative human enzymes |
| 08/22/2002 | CA2437890A1 Methods and clinical devices for the inhibition or prevention of mammalian cell growth |
| 08/22/2002 | CA2437823A1 Acrochordon alleviation |
| 08/22/2002 | CA2437811A1 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 08/22/2002 | CA2437768A1 Targetted anti-tumor drug delivery systems |
| 08/22/2002 | CA2437643A1 Matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2437588A1 Triazolo compounds as mmp inhibitors |
| 08/22/2002 | CA2437358A1 Agonists and antagonists of sphingosine-1-phosphate receptors |
| 08/22/2002 | CA2437122A1 Quinazolines as mmp-13 inhibitors |
| 08/22/2002 | CA2437118A1 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 08/22/2002 | CA2436713A1 Proteins and nucleic acids encoding same |
| 08/22/2002 | CA2436371A1 Bicyclic pyrimidine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2436195A1 Laulimalide derivatives |
| 08/22/2002 | CA2435376A1 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2434982A1 Pyridine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2434835A1 Novel modified released formulation |
| 08/22/2002 | CA2434641A1 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| 08/22/2002 | CA2434542A1 Novel modified release formulation |
| 08/22/2002 | CA2433843A1 Molecules for disease detection and treatment |
| 08/22/2002 | CA2433778A1 Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2433075A1 Benzo thiadiazine matrix metalloproteinase inhibitors |
| 08/22/2002 | CA2432111A1 Jfy1 protein induces rapid apoptosis |